BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/25/2020 2:44:03 PM | Browse: 701 | Download: 1769
 |
Received |
|
2020-06-05 10:45 |
|
Peer-Review Started |
|
2020-06-05 10:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-07-25 02:25 |
|
Revised |
|
2020-08-06 01:55 |
|
Second Decision |
|
2020-09-07 09:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-08 00:49 |
|
Articles in Press |
|
2020-09-08 00:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-10-01 22:44 |
|
Typeset the Manuscript |
|
2020-11-20 01:11 |
|
Publish the Manuscript Online |
|
2020-11-25 14:44 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Case Control Study |
| Article Title |
Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zheng-Zhi Liu, Qing Ren, Yan-Nan Zhou and Hai-Miao Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hai-Miao Yang, MSc, Chief Doctor, Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, No. 1478 Gongnong Road, Changchun 130021, Jilin Province, China. 315597629@qq.com |
| Key Words |
Esomeprazole; Proton pump inhibitor; Bioequivalence; Pharmacodynamics; Gastroesophageal reflux disease; |
| Core Tip |
The pharmacokinetic characteristic and bioequivalence of the two types of single oral dose esomeprazole magnesium enteric coated capsules were assessed. Results, the 90%CI of the ratios of geometric means of the primary pharmacokinetic parameters, all fell within the acceptable limits of 80.00%-125.00%. although meal was able to extend drug absorption, it had no impact on Cmax, AUC0-t, or AUC0-inf, of either of the two formulations under the same status. Furthermore, no significant differences of safety issues were observed between the treatment of two formulations. Therefore, the two formulations of esomeprazole magnesium enteric coated capsules are considered bioequivalence. |
| Publish Date |
2020-11-25 14:44 |
| Citation |
Liu ZZ, Ren Q, Zhou YN, Yang HM. Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects. World J Clin Cases 2020; 8(22): 5518-5528 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i22/5518.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i22.5518 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
